Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2026 19:00 ET | Source: TermPlus

Australian Retirees Look to Leverage Retirement Capital To Generate Reliable Monthly Income - TermPlus June 2026 Two-Year Fixed-Term Account Delivers 8.00%* Per Annum

Sydney, Australia, June 18, 2026 (GLOBE NEWSWIRE) -- Australia's retiree population continues to grow. Around 4.4 million Australians are now aged 65 and over. That's about 17% of the population,...
June 18, 2026 09:01 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

OCALA, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final subject has received their first dose in the Phase 2...
June 18, 2026 08:30 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

Georgia’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE...
June 17, 2026 19:00 ET | Source: TermPlus

New Diversified Monthly Income Strategy for SMSF Trustees June 2026 Update - TermPlus Launches High-Yield Fixed-Term Accounts

Sydney, Australia, June 17, 2026 (GLOBE NEWSWIRE) -- Australian superannuation regulations require self-managed super funds to maintain a documented investment strategy that covers asset allocation,...
June 17, 2026 08:47 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune...
June 17, 2026 08:00 ET | Source: Elicio Therapeutics Inc.

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer

100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based...
June 16, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight

New York, USA, June 16, 2026 (GLOBE NEWSWIRE) -- Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight The glioblastoma clinical trial...
June 16, 2026 08:33 ET | Source: Entera Bio Ltd.

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected...
June 16, 2026 07:00 ET | Source: Pasithea

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
June 16, 2026 07:00 ET | Source: NovaBridge Biosciences

NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer

Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE...